Monopar Therapeutics Inc. Profile Avatar - Palmy Investing

Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet…

Biotechnology
US, Wilmette [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Monopar Therapeutics Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of MNPR's Analysis
CIK: 1645469 CUSIP: 61023L108 ISIN: US61023L1089 LEI: - UEI: -
Secondary Listings
MNPR has no secondary listings inside our databases.